An observational study in Colorectal Cancer, sponsored by Cancer Trials Ireland. Terminated at 14 sites in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Cancer Trials Ireland · Observational
This is an exploratory, translational, non-interventional and multi-centre clinical study.
Cohort A will consist of 100 CRAC patients with stage II/III resectable disease due for adjuvant chemotherapy.
Cohort B will consist of 30 patients with stage II resectable disease for observation only.
Both cohorts will have a follow up period of up to 2 years, post chemotherapy for cohort A and post resection for cohort B.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's enrollment of 109 is below the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Cancer Trials Ireland is the lead sponsor of 69 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
100 CRAC patients with stage II/III resectable disease due for adjuvant chemotherapy.
30 CRAC patients with stage II resectable disease for observation only.
Exclusion Criteria:
Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
Stage II colorectal cancer with resectable disease for observation only
Disease free survival or progression free survival
Identify plasma biomarkers with improved sensitivity to predict early recurrence of CRAC and presence of residual occult metastases following completion of adjuvant chemotherapy
Time frame: Duration of treatment and follow up, expected to be 4 years
Accuracy, sensitivity, specificity and concordance index
To validate a panel of predictive and/or prognostic plasma biomarkers, proving its accuracy, sensitivity, specificity and concordance index.
Time frame: Duration of treatment and follow up period, expected to be 4 years
To investigate the correlation between biomarkers identified in plasma samples with the expression of the same biomarkers at tissue level.
This allows for further understanding of the role of cancer-related and/or host-related proteins in disease response and progression
Time frame: For the duration of treatment and follow up, expected to be 4 years
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cancer Trials Ireland